{"entity": "publication", "iuid": "ff6c268452fc47c584a377f416edcbe2", "timestamp": "2026-09-26T23:31:01.519Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ff6c268452fc47c584a377f416edcbe2.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ff6c268452fc47c584a377f416edcbe2"}}, "title": "Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancer.", "authors": [{"family": "Isaksson", "given": "Johan", "initials": "J"}, {"family": "Wennstr\u00f6m", "given": "Leo", "initials": "L"}, {"family": "Branden", "given": "Eva", "initials": "E"}, {"family": "Koyi", "given": "Hirsh", "initials": "H"}, {"family": "Berglund", "given": "Anders", "initials": "A"}, {"family": "Micke", "given": "Patrick", "initials": "P"}, {"family": "Mattsson", "given": "Johanna Sofia Margareta", "initials": "JSM"}, {"family": "Will\u00e9n", "given": "Linda", "initials": "L"}, {"family": "Botling", "given": "Johan", "initials": "J"}], "type": "journal article", "published": "2022-04-07", "journal": {"title": "Cancer Treat Res Commun", "issn": "2468-2942", "volume": "31", "pages": "100556", "issn-l": null}, "abstract": "Ample evidence support inflammation as a marker of outcome in non-small cell lung cancer (NSCLC). Here we explore the outcome for a subgroup of patients with advanced disease and substantially elevated systemic inflammatory activity.\n\nThe source cohort included consecutive patients diagnosed with NSCLC between January 2016 - May 2017 (n = 155). Patients with active infection were excluded. Blood parameters were examined individually, and cut-offs (ESR > 60 mm, CRP > 20 mg/L, WBC > 10 \u00d7 109, PLT > 400 \u00d7 109) were set to define the group of hyperinflamed patients. A score was developed by assigning one point for each parameter above cut-off (0-4 points).\n\nHigh systemic inflammation was associated with advanced stage and was seldom present in limited NSCLC. However, the one year survival of patients in stage IIIB-IV (n = 93) with an inflammation score of \u22652 was 0% compared to 33% and 50% among patients with a score of 1 and 0 respectively. The effect of a high inflammation score on overall survival remained significant in multi-variate analysis adjusted for confounding factors. The independent hazard ratio of an inflammation score \u2265 2 in multi-variate analysis (HR 3.43, CI 1.76-6.71) was comparable to a change in ECOG PS from 0 to 2 (HR 2.42, CI 1.13-5.18).\n\nOur results show that high level systemic inflammation is a strong independent predictor of poor survival in advanced stage NSCLC. This observation may indicate a need to use hyperinflammation as an additional clinical parameter for stratification of patients in clinical studies and warrants further research on underlying mechanisms linked to tumor progression.", "doi": "10.1016/j.ctarc.2022.100556", "pmid": "35429913", "labels": [], "xrefs": [{"db": "pii", "key": "S2468-2942(22)00046-6"}], "notes": [], "created": "2026-09-23T12:11:21.267Z", "modified": "2026-09-23T12:11:21.314Z"}